Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, +17

The Lancet Oncology

Zoledronic AcidBreast OncologyOncologyEndocrine-related CancerEndocrine Oncology +8

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Michael Gnant, Martin Filipits, Richard Greil, +21

Annals of Oncology

Surgical OncologyBreast OncologyRecurrence ScoreDistant RecurrenceCancer Recurrence +8

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger, +22

Annals of Oncology

Zoledronic AcidBreast OncologyEndocrine OncologyMedicinePharmacology +10

Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

Georg Pfeiler, Robert Königsberg, Christian Fesl, +13

Journal of Clinical Oncology

Plasmapheresis reverses all side-effects of a cisplatin overdose – a case report and treatment recommendation

G Hofmann, Thomas Bauernhofer, Peter Krippl, +7

BMC Cancer

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Michael Gnant, Ivana Šestak, Martin Filipits, +14

Annals of Oncology

Breast OncologyRecurrence ScoreMedicineGynecologyPathology +8

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, +288

Annals of Oncology

Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety +5

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

Jakob M. Riedl, Dominik A. Barth, Wolfgang M. Brueckl, +16

Cancers

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors

Daniela Schwarzenbacher, Christiane Klec, Barbara Pasculli, +17

Breast Cancer Research

miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5

Verena Stiegelbauer, Petra Vychytilova‐Faltejskova, Michael Karbiener, +19

Clinical Cancer Research